2014, Number 3
PDF size: 285.04 Kb.
ABSTRACTThere is a need to establish medication surveillance/monitoring systemsfor newborn patients in critical condition in order to protect these patients from possible adverse reactions to prescribed drugs. In accordance with Mexican official standard NOM 220, these reactions may result from pharmacological effects, interaction with other drugs, dosage errors, and the patient’s nature/idiosyncrasy. Objective: Our goal was to gain knowledge on the current situation regarding medication surveillance in neonatal intensive care units within the state of Jalisco. Material and methods: By means of a structured questionnaire involving 12 questions, an opinion poll was carried out with reference to medication surveillance programs for newborn patients in critical condition at institutions within Guadalajara’s metropolitan area and the State of Jalisco. The survey was conducted in 8 hospital centers that provide neonatal intensive care and at a state congress on pediatrics that took place in 2011. All of the respondents were asked to voluntarily fill out a questionnaire Ad-hoc, and the results were processed using the Epi Info 2010 program. Discussion and conclusions: The results show that there is widespread noncompliance of NOM 220. There is a considerable deficit with respect to units implementing medication surveillance systems and methods to notify adverse reactions to medication, with implementation rates lower than 50%. It appears that the problem is even greater in private institutions. Compliance with NOM 220 is essential in order to guarantee the quality of the care provided to newborn patients in critical condition within the state of Jalisco.
Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reaction to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999; 88: 965-8.
Hernández-Solís M, Juárez-Olguín H. Farmacovigilancia en pediatría. Acta Pediatr Mex. 2010; 31: 227-32.
Organización Mundial de la Salud. Medicamentos: seguridad y reacciones adversas. Disponible en: http://www.who.int/mediacentre/factsheets/fs293/es/index.html
Jasso-Gutiérrez L, Castellanos-Solís EC, Santos-Preciado JI. Importancia de la farmacovigilancia en pediatría. Bol Med Hosp Infant Mex. 2009; 66: 367-72.
The Uppsala monitoring center to improve worldwide patient safety. Available in: http://www.who-umc.org/
Balaguer JA, Fernández JD, Escribano J. Utilidad de una aplicación informática para disminuir errores de tratamiento en neonatología. An Esp Pediatr. 2001; 55: 541-5.
Hovstadius B, Åstrand B, Petersson G. Dispensed drugs and multiple medications in the Swedish population: an individual-based register study. BMC Clinical Pharmacology. 2009; 9: 11-6.
Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance present and future. Expert Opin Drug Saf. 2012; 11: 95-105.
Walley J, Lawn JE, Tinker A, de Francisco A, Chopra M, Rudan I et al. Lancet Alma-Ata working group. Primary health care: making Alma-Ata a reality. Lancet. 2008; 372: 1001-7.
Höpner JH, Schulte A, Thiessen J, Knuf M, Huth RG. Preparation of a compatibility chart for intravenous drug therapy in neonatal and pediatric intensive care unit. Klin Padiatr. 2007; 219: 37-43.
López-Alarcón M, Bernabe-García M, Del Prado M, Rivera D, Ruiz G, Maldonado J et al. Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates. Nutrition. 2006; 22: 731-7.
Aguirre E, Durán ME, Zambudio GA, González R, Castaño I, Cárceles MD et al. Post-surgical paediatric pain: nursing-PCA versus continuous I.V. infusion of tramadol. Cir Pediatr. 2003; 16: 30-3.
DosReis S, Zito JM, Safer DJ, Soeken KL. Mental health services for youths in foster care and disabled youths. Am J Public Health. 2001; 91: 1094-9.
Macnab AJ, Noble R, Smart P, Green G. Narcotics and controlled drugs: a secure system for access by transport teams. Air Med J. 1998; 17: 73-5.
Gutiérrez-Padilla JA, Martínez-Verónica R, Angulo-Castellanos E, López-Vargas L, de la Torre-Gutiérrez M, Aguilar-Villanueva M et al. Diagnóstico de neurodiscapacidad en el periodo neonatal en México. Resultados de una encuesta realizada al personal de salud. Perinatol Reprod Hum. 2012; 26: 30-4.
Zepeda-Romero LC, Barrera de León JC, Camacho-Choza C, González-Bernal C, Camarena-Garcia E, Díaz-Alatorre C et al. Retinopathy of prematurity as a major cause of severe visual impairment and blindness in children in schools for the blind in Guadalajara city, Mexico. Br J Ophthalmol. 2011; 95: 1502-5.
Lehmann Ch, Johnson K, Del Beccaro M, Alexander G, Drummond W, Francis A et al. Electronic prescribing in pediatrics: toward safer and more effective medication management. Council on clinical information technology executive committee, 2011-2012. Pediatrics. 2013. doi: 10.1542/peds.2013-0192.